Effect of incretins on skeletal health.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2023-08-01 Epub Date: 2023-06-12 DOI:10.1097/MED.0000000000000813

Jakob Starup-Linde, Katrine Hygum, Bente Langdahl

{"title":"Effect of incretins on skeletal health.","authors":"Jakob Starup-Linde, Katrine Hygum, Bente Langdahl","doi":"10.1097/MED.0000000000000813","DOIUrl":null,"url":null,"abstract":"Purpose of review: The incretin hormones, glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have been shown to decrease bone resorption in humans. The aim of this review is to collate evidence and current advances in the research within the last year on the effect of incretins on skeletal health.Recent findings: Preclinical studies show potential direct beneficial effects on bone by GLP-1 and GIP, however real world epidemiological data show no effects of GLP-1 receptor analogues on fracture risk. This may be due to the weight loss accompanied by GLP-1 treatment which may have detrimental effects on bone. GIP is shown to reduce bone resorption and increase bone formation. Further evidence suggests an additive effect of GIP and glucagon like peptide-2, which could affect bone by different mechanisms.Summary: GIP and GLP-1 based therapies are more widespread used and may have potential beneficial effects on bone, possibly counterbalanced by weight loss. Long-term effects and side-effects of GIP or GIP/ GLP-2 co-administration remain to be elucidated, and longer term treatment trials are needed.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 4","pages":"206-212"},"PeriodicalIF":2.6000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrinology & Diabetes and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MED.0000000000000813","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The incretin hormones, glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have been shown to decrease bone resorption in humans. The aim of this review is to collate evidence and current advances in the research within the last year on the effect of incretins on skeletal health.

Recent findings: Preclinical studies show potential direct beneficial effects on bone by GLP-1 and GIP, however real world epidemiological data show no effects of GLP-1 receptor analogues on fracture risk. This may be due to the weight loss accompanied by GLP-1 treatment which may have detrimental effects on bone. GIP is shown to reduce bone resorption and increase bone formation. Further evidence suggests an additive effect of GIP and glucagon like peptide-2, which could affect bone by different mechanisms.

Summary: GIP and GLP-1 based therapies are more widespread used and may have potential beneficial effects on bone, possibly counterbalanced by weight loss. Long-term effects and side-effects of GIP or GIP/ GLP-2 co-administration remain to be elucidated, and longer term treatment trials are needed.

查看原文本刊更多论文

胰蛋白酶对骨骼健康的影响

综述的目的：增量素激素、胰高血糖素样肽-1（GLP-1）和胃抑制肽（GIP）已被证明可减少人体骨吸收。本综述旨在整理去年有关胰高血糖素对骨骼健康影响的证据和最新研究进展：临床前研究显示，GLP-1 和 GIP 对骨骼有潜在的直接益处，但现实世界的流行病学数据显示，GLP-1 受体类似物对骨折风险没有影响。这可能是因为 GLP-1 治疗会导致体重减轻，而体重减轻可能会对骨骼产生不利影响。GIP 可减少骨吸收，增加骨形成。更多证据表明，GIP 和胰高血糖素样肽-2 具有叠加效应，可通过不同机制影响骨骼。小结：基于 GIP 和 GLP-1 的疗法得到了更广泛的应用，可能会对骨骼产生潜在的有益影响，但可能会被体重减轻所抵消。GIP 或 GIP/ GLP-2 联合用药的长期效果和副作用仍有待阐明，需要进行更长期的治疗试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Endocrinology & Diabetes and Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.80

自引率

3.10%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Endocrinology, Diabetes and Obesity delivers a broad-based perspective on the most recent and exciting developments in the field from across the world. Published bimonthly and featuring twelve key topics – including androgens, gastrointestinal hormones, diabetes and the endocrine pancreas, and neuroendocrinology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.